ExodusPoint Capital Management LP Has $2.32 Million Holdings in Elanco Animal Health Incorporated (NYSE:ELAN)

ExodusPoint Capital Management LP decreased its position in Elanco Animal Health Incorporated (NYSE:ELAN) by 81.5% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 191,283 shares of the company’s stock after selling 843,055 shares during the quarter. ExodusPoint Capital Management LP’s holdings in Elanco Animal Health were worth $2,316,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of ELAN. Wilmington Savings Fund Society FSB acquired a new stake in Elanco Animal Health in the 3rd quarter valued at $35,000. Jones Financial Companies Lllp raised its holdings in Elanco Animal Health by 95.6% during the fourth quarter. Jones Financial Companies Lllp now owns 4,212 shares of the company’s stock worth $51,000 after acquiring an additional 2,059 shares in the last quarter. SRS Capital Advisors Inc. boosted its position in Elanco Animal Health by 221.2% during the fourth quarter. SRS Capital Advisors Inc. now owns 4,953 shares of the company’s stock valued at $60,000 after purchasing an additional 3,411 shares during the last quarter. MRP Capital Investments LLC bought a new position in Elanco Animal Health in the fourth quarter valued at approximately $61,000. Finally, Blue Trust Inc. increased its position in shares of Elanco Animal Health by 47.7% during the 4th quarter. Blue Trust Inc. now owns 5,862 shares of the company’s stock worth $71,000 after purchasing an additional 1,894 shares during the last quarter. 97.48% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

ELAN has been the subject of several analyst reports. Piper Sandler decreased their target price on shares of Elanco Animal Health from $16.00 to $12.00 and set a “neutral” rating for the company in a research note on Thursday, March 6th. Barclays reduced their price target on Elanco Animal Health from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Wednesday, February 26th. Stifel Nicolaus lowered their price target on Elanco Animal Health from $18.00 to $16.00 and set a “buy” rating on the stock in a research report on Friday, February 21st. UBS Group cut their price objective on Elanco Animal Health from $18.00 to $17.00 and set a “buy” rating for the company in a research report on Wednesday, February 26th. Finally, Morgan Stanley decreased their target price on Elanco Animal Health from $14.00 to $13.00 and set an “equal weight” rating on the stock in a report on Wednesday, February 26th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $15.17.

Elanco Animal Health Stock Performance

NYSE:ELAN opened at $8.95 on Tuesday. The company has a current ratio of 2.55, a quick ratio of 1.31 and a debt-to-equity ratio of 0.66. The stock has a 50 day simple moving average of $10.97 and a 200 day simple moving average of $12.23. Elanco Animal Health Incorporated has a 1-year low of $8.44 and a 1-year high of $18.80. The stock has a market cap of $4.44 billion, a P/E ratio of 22.36, a PEG ratio of 2.50 and a beta of 1.44.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Tuesday, February 25th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.01). Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. The business had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.01 billion. During the same period in the previous year, the firm posted $0.08 EPS. The company’s revenue was down 1.4% compared to the same quarter last year. Research analysts anticipate that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Insider Activity

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, March 11th. The shares were bought at an average price of $10.20 per share, for a total transaction of $102,000.00. Following the completion of the transaction, the director now owns 111,459 shares of the company’s stock, valued at approximately $1,136,881.80. This trade represents a 9.86 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. 0.57% of the stock is owned by company insiders.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.